Now live: Pro — the full 13F research suite for serious investorsSee pricing →
JOHNSON & JOHNSON (JNJ)

Q2 2023 · 13F-HR

JOHNSON & JOHNSON (JNJ)holdings as filed

Filed 2023-08-02 · accession 0000904454-23-000459

$322.1M
Reported value
22
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74366E102PTGXProtagonist Therapeutics Inc.$67.6M21.0%2,449,183CommonSHARED
52490G102LEGNLegend Biotech Corporation$56.2M17.5%814,586CommonSHARED
126638105CVRXCVRx, Inc.$54.0M16.8%3,495,575CommonSHARED
G59665102MGTXMeiraGTx Holdings plc$44.6M13.9%6,641,064CommonSHARED
98401F105XNCRXencor, Inc.$18.7M5.80%748,062CommonSHARED
36118A100Fusion Pharmaceuticals Inc.$17.1M5.32%3,670,516CommonSHARED
31189P102FATEFate Therapeutics, Inc.$16.1M4.99%3,379,064CommonSHARED
74276L105PRCTProcept BioRobotics Corporation$12.7M3.93%357,939CommonSHARED
730541109Point Biopharma Global Inc.$9.1M2.81%1,000,000CommonSHARED
04280A100ARWRArrowhead Pharmaceuticals, Inc.$8.8M2.74%247,598CommonSHARED
M70700105NNOXNano-X Imaging Ltd.$4.9M1.53%317,704CommonSHARED
929033108Vor Biopharma, Inc.$3.3M1.03%1,074,658CommonSHARED
01438T106ALDXAldeyra Therapeutics, Inc.$3.3M1.03%394,834CommonSHARED
229790100HLTHQCue Health, Inc.$2.0M0.64%5,548,864CommonSHARED
007002108TORCEURAdicet Bio, Inc.$1.8M0.55%728,944CommonSHARED
09090D103BiomX Inc.$768,0250.24%2,133,402CommonSHARED
83444K105SLGCUSDSomaLogic, Inc.$649,2300.20%281,052CommonSHARED
185063104CLSDUSDClearside Biomedical, Inc.$189,9840.06%169,629CommonSHARED
G0411D107APLMApollomics, Inc.$75,9340.02%13,252CommonSHARED
81727U105SENS1GBPSenseonics Holdings, Inc.$41,6810.01%54,621CommonSHARED
89237H209Tracon Pharmaceuticals, Inc.$24,4450.01%84,003CommonSHARED
14888D208Catalyst Biosciences, Inc.$23,5400.01%66,951CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.